Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

OncoSec Medical Incorporated ONCSQ OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
23/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

OncoSec Medical Incorporated (ONCSQ) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $34M (loss), growing at -7.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $6M equity (Debt-to-Equity (D/E) ratio 1.01, moderate). Current ratio is 2.3 (strong liquidity). Debt-to-assets is 28.2%. Total assets: $22M.

Analyst outlook: 0 / 1 analysts rate ONCSQ as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

ONCSQ SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ONCSQ

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ONCSQ: +0%/yr revenue is, -7.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ONCSQ: Debt-to-Equity (D/E) ratio 1.01 (moderate), Current ratio is 2.3 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ONCSQ: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate ONCSQ as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.0001
Volume123.29K
Avg Volume (30D)54.59K
Market Cap$596.00
Beta (1Y)9.96
Share Statistics
EPS (TTM)-19.13
Shares Outstanding$1.79M
IPO Date2010-04-07
Employees40
Financial Highlights & Ratios
Gross Profit$-1.07M
EBITDA$-36.43M
Net Income$-34.18M
Operating Income$-37.01M
Total Cash$12.3M
Total Debt$6.17M
Net Debt$-6.12M
Total Assets$21.88M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS68234L4059

Price Chart

Track all markets on TradingView
ONCSQ
OncoSec Medical Incorporated ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.00

People Also View

LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
 RHHBF
RHHBF
Roche Holding AG
$415.00
-0.84%
 RHHBY
RHHBY
Roche Holding AG
$50.99
-0.08%
 AZN
AZN
AstraZeneca PLC
$201.21
-1.55%
 NVS
NVS
Novartis AG
$152.08
-0.85%
 MRK
MRK
Merck & Co., Inc.
$117.90
-1.72%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message